Here below are the publications (7) participated by Andrea Rinaldi along with Jacopo Sgrignani (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers

Haematologica, 1 novembre 2024

2) PI3Kδ activation, IL6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Blood Advances, 7 ottobre 2024

3) Targeting senescence induced by age or chemotherapy with a polyphenol-rich natural extract improves longevity and healthspan in mice
nature aging, 1 luglio 2024

4) A first-in-class Wiskott-Aldrich syndrome protein activator with anti-tumor activity in hematologic cancers
haematologica, 20 giugno 2024

5) PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
bioRxiv, 16 novembre 2023

6) ETS1 phosphorylation at threonine 38 is associated with the cell of origin of diffuse large B cell lymphoma and sustains the growth of tumour cells
British Journal of Haematology, 16 agosto 2023

7) EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer
Nature Communications, 6 luglio 2021